Diverse cutaneous side effects associated with BRAF inhibitor therapy: A clinicopathologic study

BACKGROUND: Vemurafenib, a novel selective small molecule inhibitor of BRAF, has recently been shown to be effective in the treatment of melanomas harboring the BRAF V600E mutation. Similar to the broad-spectrum RAF inhibitor sorafenib, vemurafenib induces development of squamous cell carcinomas and...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:J Am Acad Dermatol
Egile Nagusiak: Chu, Emily Y., Wanat, Karolyn A., Miller, Christopher J., Amaravadi, Ravi K., Fecher, Leslie A., Brose, Marcia S., McGettigan, Suzanne, Giles, Lydia R., Schuchter, Lynn M., Seykora, John T., Rosenbach, Misha
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2012
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4838029/
https://ncbi.nlm.nih.gov/pubmed/22609219
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jaad.2012.04.008
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak